VALEANT PHARMS INTL Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for VALEANT PHARMS INTL, and what generic alternatives to VALEANT PHARMS INTL drugs are available?
VALEANT PHARMS INTL has five approved drugs.
There are seven US patents protecting VALEANT PHARMS INTL drugs.
There are sixty-two patent family members on VALEANT PHARMS INTL drugs in sixteen countries and five supplementary protection certificates in five countries.
Summary for VALEANT PHARMS INTL
| International Patents: | 62 |
| US Patents: | 7 |
| Tradenames: | 5 |
| Ingredients: | 4 |
| NDAs: | 5 |
Drugs and US Patents for VALEANT PHARMS INTL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valeant Pharms Intl | LACRISERT | hydroxypropyl cellulose | INSERT;OPHTHALMIC | 018771-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
| Valeant Pharms Intl | COLAZAL | balsalazide disodium | CAPSULE;ORAL | 020610-001 | Jul 18, 2000 | AB | RX | Yes | Yes | 7,452,872*PED | See Plans and Pricing | Y | See Plans and Pricing | ||
| Valeant Pharms Intl | CUPRIMINE | penicillamine | CAPSULE;ORAL | 019853-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | |||||
| Valeant Pharms Intl | GIAZO | balsalazide disodium | TABLET;ORAL | 022205-001 | Feb 3, 2012 | DISCN | Yes | No | 9,192,616 | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VALEANT PHARMS INTL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Valeant Pharms Intl | APRISO | mesalamine | CAPSULE, EXTENDED RELEASE;ORAL | 022301-001 | Oct 31, 2008 | 6,551,620 | See Plans and Pricing |
| Valeant Pharms Intl | COLAZAL | balsalazide disodium | CAPSULE;ORAL | 020610-001 | Jul 18, 2000 | 4,412,992*PED | See Plans and Pricing |
| Valeant Pharms Intl | APRISO | mesalamine | CAPSULE, EXTENDED RELEASE;ORAL | 022301-001 | Oct 31, 2008 | 8,940,328 | See Plans and Pricing |
| Valeant Pharms Intl | GIAZO | balsalazide disodium | TABLET;ORAL | 022205-001 | Feb 3, 2012 | 6,197,341 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for VALEANT PHARMS INTL drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsules | 0.375 g | ➤ Subscribe | 2012-04-03 |
| ➤ Subscribe | Tablets | 1.1 g | ➤ Subscribe | 2013-11-05 |
International Patents for VALEANT PHARMS INTL Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Israel | 212057 | See Plans and Pricing |
| Australia | 2009298139 | See Plans and Pricing |
| Japan | 2013032395 | See Plans and Pricing |
| Canada | 3004028 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for VALEANT PHARMS INTL Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2826776 | 122021000025 | Germany | See Plans and Pricing | PRODUCT NAME: EINE KOMBINATION VON (A) (R)-1-(2,2-DIFLUORBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUOR-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANCARBOXAMID ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON UND (B) N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-CHINOLIN-3-CARBOXAMID ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1306 20181031 |
| 2826776 | 2021C/517 | Belgium | See Plans and Pricing | PRODUCT NAME: SYMKEVI - TEZACAFTOR/IVACAFTOR; EEN COMBINATIE VAN (A) (R)-1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE OF EEN VANUIT FARMACEUTISCH OOGPUNT GESCHIKT ZOUT DAARVAN EN (B) N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE OF EEN VANUIT FARMACEUTISCH OOGPUNT GESCHIKT ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/18/1306 20181106 |
| 2826776 | 301105 | Netherlands | See Plans and Pricing | PRODUCT NAME: EEN COMBINATIE VAN (A) (R)-1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUOR-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPAANCARBOXAMIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN (B) N-(5-HYDROXY-2,4-DITERT-BUTYL-FENYL)-4-OXO-1H-CHINOLINE-3-CARBOXAMIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/18/1306 20181106 |
| 2826776 | LUC00207 | Luxembourg | See Plans and Pricing | PRODUCT NAME: A COMBINATION OF (A) (R)-1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND (B) N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/18/1306 20181106 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
